Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy
Malignant glioblastoma (GBM) is the most aggressive brain cancer that has a very low survival rate. With the rapid development of nanotechnology in the past few decades, the use of nanoparticles (NPs) for nucleic acid delivery is expected to have a revolutionary impact on GBM therapy. However, clini...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01194/full |
| _version_ | 1818872551464501248 |
|---|---|
| author | Phei Er Saw Phei Er Saw Ao Zhang Ao Zhang Yan Nie Yan Nie Lei Zhang Lei Zhang Yingjie Xu Xiaoding Xu Xiaoding Xu |
| author_facet | Phei Er Saw Phei Er Saw Ao Zhang Ao Zhang Yan Nie Yan Nie Lei Zhang Lei Zhang Yingjie Xu Xiaoding Xu Xiaoding Xu |
| author_sort | Phei Er Saw |
| collection | DOAJ |
| description | Malignant glioblastoma (GBM) is the most aggressive brain cancer that has a very low survival rate. With the rapid development of nanotechnology in the past few decades, the use of nanoparticles (NPs) for nucleic acid delivery is expected to have a revolutionary impact on GBM therapy. However, clinical success in GBM therapy remains a formidable challenge, mainly due to suboptimal in vivo delivery of therapeutics to glioma cells. Herein, we developed an aptamer-like peptide (aptide)-decorated liposomal nanoplatform for systemic small interfering RNA (siRNA) delivery and targeted GBM therapy. This nanoplatform is mainly composed of the following key components: (i) classic liposome structure with an aqueous core that can encapsulate therapeutic siRNA; (ii) hydrophilic polyethylene glycol (PEG) chains on the outer shell to prolong blood circulation; and (iii) surface-encoded aptide to specifically target the extra-domain B (EDB) of fibronectin that over-expressed on glioma cells. After systemic administration of these new siRNA delivery NPs, they can target the glioma cells and efficiently inhibit the GBM tumor growth by silencing the expression of cyclophilin A (CypA), which is up-regulated in brain cancer and plays an important role in malignant transformation of brain cancer and maintaining glioma cell stemness. These results suggest that the reported RNA interference (RNAi) NP platform herein could become an effective tool for targeted GBM therapy. |
| first_indexed | 2024-12-19T12:40:37Z |
| format | Article |
| id | doaj.art-c79099b27aa7495e9ba44af486ce809a |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-19T12:40:37Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c79099b27aa7495e9ba44af486ce809a2022-12-21T20:20:59ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-10-01910.3389/fphar.2018.01194421405Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma TherapyPhei Er Saw0Phei Er Saw1Ao Zhang2Ao Zhang3Yan Nie4Yan Nie5Lei Zhang6Lei Zhang7Yingjie Xu8Xiaoding Xu9Xiaoding Xu10Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaRNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaRNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaRNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaRNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaMalignant glioblastoma (GBM) is the most aggressive brain cancer that has a very low survival rate. With the rapid development of nanotechnology in the past few decades, the use of nanoparticles (NPs) for nucleic acid delivery is expected to have a revolutionary impact on GBM therapy. However, clinical success in GBM therapy remains a formidable challenge, mainly due to suboptimal in vivo delivery of therapeutics to glioma cells. Herein, we developed an aptamer-like peptide (aptide)-decorated liposomal nanoplatform for systemic small interfering RNA (siRNA) delivery and targeted GBM therapy. This nanoplatform is mainly composed of the following key components: (i) classic liposome structure with an aqueous core that can encapsulate therapeutic siRNA; (ii) hydrophilic polyethylene glycol (PEG) chains on the outer shell to prolong blood circulation; and (iii) surface-encoded aptide to specifically target the extra-domain B (EDB) of fibronectin that over-expressed on glioma cells. After systemic administration of these new siRNA delivery NPs, they can target the glioma cells and efficiently inhibit the GBM tumor growth by silencing the expression of cyclophilin A (CypA), which is up-regulated in brain cancer and plays an important role in malignant transformation of brain cancer and maintaining glioma cell stemness. These results suggest that the reported RNA interference (RNAi) NP platform herein could become an effective tool for targeted GBM therapy.https://www.frontiersin.org/article/10.3389/fphar.2018.01194/fullnanoparticleaptidesiRNAtargeted deliveryglioblastoma |
| spellingShingle | Phei Er Saw Phei Er Saw Ao Zhang Ao Zhang Yan Nie Yan Nie Lei Zhang Lei Zhang Yingjie Xu Xiaoding Xu Xiaoding Xu Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy Frontiers in Pharmacology nanoparticle aptide siRNA targeted delivery glioblastoma |
| title | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
| title_full | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
| title_fullStr | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
| title_full_unstemmed | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
| title_short | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
| title_sort | tumor associated fibronectin targeted liposomal nanoplatform for cyclophilin a sirna delivery and targeted malignant glioblastoma therapy |
| topic | nanoparticle aptide siRNA targeted delivery glioblastoma |
| url | https://www.frontiersin.org/article/10.3389/fphar.2018.01194/full |
| work_keys_str_mv | AT pheiersaw tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT pheiersaw tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT aozhang tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT aozhang tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT yannie tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT yannie tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT leizhang tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT leizhang tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT yingjiexu tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT xiaodingxu tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy AT xiaodingxu tumorassociatedfibronectintargetedliposomalnanoplatformforcyclophilinasirnadeliveryandtargetedmalignantglioblastomatherapy |